Making effective decisions in health care requires a thorough understanding of the patient perspective, as well as robust, precise measures of response to therapy. The Patient Access & Affordability Project evaluates the various frameworks used to assess and demonstrate the value of new treatments to ensure that the patient is kept at the center of health care decisions.
Get Updates in Your Inbox
Sign Up. Stay Informed.
The Conversation
Recommended Reading: The pandemic will end at your local pharmacy — if we let it
by Rick Gates, Rich Tremonte, & Robert Popovian The date when the U.S. Food and Drug Administration authorized the Pfizer-BioNTech COVID-19 vaccine for emergency use, Dec. 11, 2020, was a seminal moment in human achievement. Never had a safe and effective vaccine...
Recommended Reading: We Need Greater Transparency to Improve the U.S. Healthcare System
By Robert Popovian and Wayne Winegarden The time has come for us to think about incremental, evolutionary, and targeted changes to the healthcare system to reduce costs rather than focusing on grand bargains. It is time for practical solutions that will likely have...
Something is Rotten in the State of Colorado
Last month, members of the Colorado General Assembly introduced a bill intended to lower prescription drug costs in the state. The legislation (Senate Bill 21-175) would create a Prescription Drug Affordability Review Board to set payment caps on drugs deemed to be...
Last Word: ICER’s flawed pricing recommendations for new high cholesterol treatments
On the March 2, 2021, the Institute for Clinical and Economic Review (ICER) released its final evidence report on three emerging treatments for high cholesterol patients: inclisiran (Novartis), bempedoic acid and bempedoic acid/ezetimibe (Esperion Therapeutics). Not...
Comments on ICER’s February 11th Draft Evidence Report, “Anti B-Cell Maturation Antigen CAR T-cell and Antibody Drug Conjugate Therapy for Heavily Pre-Treated Relapsed and Refractory Multiple Myeloma.
Comments on ICER's February 11, 2021 Draft Evidence Report “Anti B-Cell Maturation Antigen CAR T-cell and Antibody Drug Conjugate Therapy for Heavily Pre-Treated Relapsed and Refractory Multiple Myeloma”. Some of the concerns raised in the letter point out that the...
Recommended Reading: President Biden’s Bipartisan Opportunity to Reduce Patients’ Drug Costs
By Robert Popovian & Wayne Winegarden March 1, 2021 President Joe Biden should take advantage of a bipartisan opportunity to meaningfully reduce patients’ out-of-pocket spending on biopharmaceuticals. Seizing this opportunity requires the president to recognize...